RS-5 / Resolute Science - LARVOL DELTA

Resolute Science Receives FDA Orphan Drug Designation for its Lead Therapeutic, RS-5, for Soft Tissue Sarcomas (PRWeb) - "This regulatory milestone underscores RS-5's therapeutic potential and supports the company's continued progress toward initiating first-in-human clinical trials in 2026."

New trial • Orphan drug • Soft Tissue Sarcoma